The deal is sourced from Luminex's own 8-K exhibit (filed April 12, 2021) and a later DEFM14A proxy amendment covering the fairness opinion, both of which are primary company disclosures rather than secondary reporting. The transaction proceeded to a stockholder vote process, consistent with a negotiated merger rather than an unsolicited approach.
Perella Weinberg Partners acted as financial advisor to Luminex, the target, per the press release language: "Perella Weinberg Partners acted as financial advisor to Luminex Corporation and DLA Piper LLP (US) acted as legal advisor." On the acquirer side, Morgan Stanley & Co. International PLC served as DiaSorin's lead financial advisor, with Citigroup Global Markets Europe AG also advising DiaSorin and Mediobanca providing a separate fairness opinion to DiaSorin's board.
DLA Piper LLP (US) served as legal advisor to Luminex. On the DiaSorin side, Cravath, Swaine & Moore LLP and Pedersoli Studio Legale (an Italian law firm, reflecting DiaSorin's Italian domicile) served as legal advisors.
The source documents reviewed did not disclose an aggregate deal value, consideration mix, or expected closing date in the excerpts captured; a separate DEFM14A amendment discusses Perella Weinberg's fairness-opinion analysis and discloses approximately $3.25 million in prior unrelated capital-markets fees paid to Perella Weinberg by Luminex, but does not restate the headline transaction value.
Not disclosed in the reviewed materials: the aggregate purchase price, the per-share consideration, the cash/stock mix, and the expected closing timeline. These would need to be sourced from the original January 2021 deal-announcement 8-K or the DEFM14A's summary term sheet for a complete record.